Gufic Biosciences (509079) Q3 25/26 earnings summary

Executive summary

• Domestic branded business focuses on protocol-led depth, science-backed differentiation, and execution in hospital injectables, women's health, toxin, and Nutra Ayurveda platforms, with robust R&D and international expansion.

• Achieved commercial production at the advanced Indore injectable facility, targeting global regulated markets and reaching 30% utilization in Q3 FY25.

• International business advanced with regulatory approvals in Germany, Portugal, Lithuania, Myanmar, and Oman, expanding registrations and direct EU access.

• Strong partnerships and licensing deals with global pharma and biotech leaders, including a strategic licensing agreement for fillers and investment in Selvax cancer vaccine therapy.

• Standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2025, were reviewed and approved by the Board, with no material misstatements found by auditors.

Financial highlights

• Q3 FY26 revenue was ₹231.1 Cr, up from ₹207.8 Cr in Q3 FY25; 9M FY26 revenue at ₹688.4 Cr, up from ₹614.8 Cr YoY.

• Q3 FY26 EBITDA was ₹37.1 Cr (16.05% margin), down from 17.23% in Q3 FY25; 9M FY26 EBITDA at ₹108.2 Cr.

• Q3 FY26 PAT was ₹15.6 Cr (6.75% margin), down from ₹19.3 Cr (9.29%) in Q3 FY25; 9M FY26 PAT at ₹42.6 Cr.

• Standalone revenue for the quarter was ₹23,109.36 lakhs, with consolidated revenue at ₹23,220.04 lakhs; standalone net profit was ₹1,556.39 lakhs, consolidated net profit was ₹1,682.40 lakhs.

• Historical trend shows declining margins over recent years.

Outlook and guidance

• FY27 revenue growth guidance set at a minimum of 15%, with potential upside to 20% if positive factors materialize.

• Indore facility expected to be margin accretive by FY27, with global regulatory clearances and US FDA readiness by FY29.

• Export revenue from Indore to Europe and regulated markets expected to start in Q3/Q4 FY27, following EU GMP audit completion.

• Strategic roadmap targets 5-10% market share in identified geographies over 3-5 years.

• The company operates in a single segment: Pharmaceuticals.